Exposure of Bisphenol‐A in breast cancer patients‐quantitatively assessed by a sensitivity‐enhanced high performance liquid chromatography coupled with fluorescence detector: A Case‐Control Study

2021 ◽  
Author(s):  
Sivaselvakumar Muthusamy ◽  
Susipriya Palanisamy ◽  
Sudha Ramalingam
2020 ◽  
Author(s):  
Yi Zheng ◽  
Meng Wang ◽  
Shuqian Wang ◽  
Peng Xu ◽  
Yujiao Deng ◽  
...  

Abstract Background: LncRNA MEG3 expressed abnormally in various cancers including breast cancer, but no studies reported the correlation between MEG3 SNPs and breast cancer susceptibility among Chinese women. Methods: This study is aimed to explore the association between three SNPs of MEG3 (rs3087918, rs7158663, rs11160608) and breast cancer. The study is a population-based case-control study including 434 breast cancer patients and 700 healthy controls. Genotyping was performed using Sequenom MassArray technique. Function prediction of rs3087918 were based on RNAfold and lncRNASNP2 databases. Results: Pooled analysis indicated that rs3087918 was related to a decreased risk of breast cancer (GG vs. TT: OR(95%) = 0.67(0.45-0.99), P = 0.042; GG vs. TT + TG: OR(95%) = 0.69(0.48-0.99), P = 0.046), especially for women aged <=49 (GG vs. TT: OR(95%) = 0.40(0.22-0.73), P = 0.02). Comparison between case groups showed genotype GG and TG/GG of rs3087918 were correlated with her-2 receptor expression (GG vs. TT: OR(95%) = 2.37(1.24-4.63), P = 0.010; TG + GG vs. TT: OR(95%) = 1.50(1.01-2.24), P = 0.045). We didn’t find statistical significance for rs11160608, rs7158663 and breast cancer. Structure prediction based on RNAfold found rs3087918 may influence the secondary structure of MEG3. The results based on lncRNASNP2 indicated that rs3087918 may gain the targets of hsa-miR-1203 to MEG3, while loss the target of hsa-miR-139-3p and hsa-miR-5091 to MEG3. Conclusions: MEG3 rs3087918 was associated with a decreased risk of breast cancer. MEG3 haplotype TCG may increase the risk of breast cancer.


1981 ◽  
Vol 67 (5) ◽  
pp. 443-445 ◽  
Author(s):  
Mario Cappellini ◽  
Stefano Ciatto ◽  
Raffaello Mungai

The role of postoperative radiotherapy in N- breast cancer with centrally or medially located tumors is still controversial. The authors report the results of a retrospective non-randomized case-control study of T1–2 N- breast cancer patients with centrally or medially located tumors, treated or not with postoperative radiotherapy after radical mastectomy. Sixty-four patients were treated with postoperative radiotherapy (Co-60) to the internal mammary chain and supraclavicular nodes. Sixty-four control cases, matched by T size and site, N status, age and menstrual status and simply followed-up after radical mastectomy were selected. No significant differences in actuarial recurrence and NED survival rates were observed at 5 years in the 2 compared groups, thus indicating that postoperative radiotherapy for patients with N- centrally or medially located breast cancers is not worthwhile treatment policy.


2019 ◽  
Vol 28 (3) ◽  
pp. 237
Author(s):  
OlabumuyiAdeniyi Adedayo ◽  
AAbdus-salam Abbas ◽  
OgunnorinBabatunde Olutoye ◽  
AAdenipekun Adeniyi ◽  
Olabumuyi Olayide

2001 ◽  
Vol 38 (2-3) ◽  
pp. 200-208 ◽  
Author(s):  
David P. Atencio ◽  
Christopher M. Iannuzzi ◽  
Sheryl Green ◽  
Richard G. Stock ◽  
Jonine L. Bernstein ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document